Blood Cancer Journal - Table of Contents alert Volume 4 May 2014

If you are unable to see the message below, click here to view.

Advertisement BD FACSCanto™ has 10-color capability. Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences. bdbiosciences.com/go/canto   TABLE OF CONTENTS Volume 4, May 2014 In this issue Reviews Original Articles Letters to the Editor Sign up for e-alerts Web feed Advertisement Blood Cancer Journal: now fully indexed in PubMed.  The journal covers pre-clinical and clinical work in the field of hematology with ramifications into translational biology research down to new therapies. Submit your paper today and benefit from rapid decision and publication.    Reviews Top The role of epigenetics in the biology of multiple myeloma K Dimopoulos, P Gimsing and K Grønbæk Blood Cancer J 2014 4: e207; 10.1038/bcj.2014.29 Abstract | Full Text Induced pluripotent stem cells in hematology: current and future applications D Focosi, G Amabile, A Di Ruscio, P Quaranta, D G Tenen and M Pistello Blood Cancer J 2014 4: e211; 10.1038/bcj.2014.30 Abstract | Full Text Original Articles Top T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS A M Aalbers, M M van den Heuvel-Eibrink, I Baumann, H B Beverloo, G J Driessen, M Dworzak, A Fischer, G Göhring, H Hasle, F Locatelli, B De Moerloose, P Noellke, M Schmugge, J Stary, A Yoshimi, M Zecca, C M Zwaan, J J M van Dongen, R Pieters, C M Niemeyer, V H J van der Velden and A W Langerak Blood Cancer J 2014 4: e209; 10.1038/bcj.2014.28 Abstract | Full Text The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas R Briski, A L Feldman, N G Bailey, M S Lim, K Ristow, T M Habermann, W R Macon, D J Inwards, J P Colgan, G S Nowakowski, M S Kaminski, T E Witzig, S M Ansell and R A Wilcox Blood Cancer J 2014 4: e214; 10.1038/bcj.2014.34 Abstract | Full Text Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML D L Stirewalt, E L Pogosova-Agadjanyan, K Tsuchiya, J Joaquin and S Meshinchi Blood Cancer J 2014 4: e208; 10.1038/bcj.2014.27 Abstract | Full Text TALEN-mediated genetic tailoring as a tool to analyze the function of acquired mutations in multiple myeloma cells X Wu, P R Blackburn, R C Tschumper, S C Ekker and D F Jelinek Blood Cancer J 2014 4: e210; 10.1038/bcj.2014.32 Abstract | Full Text Letters to the Editor Top Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma P Campbell, P Walker, S Avery, S Patil, D Curtis, A Schwarer, A Wei, A Kalff, J Muirhead and A Spencer Blood Cancer J 2014 4: e213; 10.1038/bcj.2014.33 Full Text European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation B C Medeiros, L Tian, S Robenson, G G Laport, L J Johnston, J A Shizuru, D B Miklos, S Arai, J E Benjamin, W-K Weng, R S Negrin and R Lowsky Blood Cancer J 2014 4: e216; 10.1038/bcj.2014.35 Full Text Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients H Reinhard, S Yousef, T Luetkens, B Fehse, B Berdien, N Kröger and D Atanackovic Blood Cancer J 2014 4: e212; 10.1038/bcj.2014.31 Full Text Inactivation of BANK1 in a novel IGH-associated translocation t(4;14)(q24;q32) suggests a tumor suppressor role in B-cell lymphoma J Yan, K Nie, S Mathew, Y Tam, S Cheng, D M Knowles, A Orazi and W Tam Blood Cancer J 2014 4: e215; 10.1038/bcj.2014.36 Full Text Advertisement Don't miss these recently published articles, currently popular with your colleagues:  The evolution of clinical trials for infant acute lymphoblastic leukemia   5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies    You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.